<DOC>
	<DOCNO>NCT00121628</DOCNO>
	<brief_summary>The purpose study determine AMG 706 clinically meaningful anti-tumor activity subject locally advanced metastatic thyroid cancer candidate radioactive iodine therapy local therapy .</brief_summary>
	<brief_title>A Phase 2 , Open-label Study AMG 706 Treat Subjects With Locally Advanced Metastatic Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic thyroid cancer Measurable disease Normal blood pressure ( history hypertension , blood pressure must control medication ) Evidence disease progression within 6 month start study ( differentiate thyroid cancer subject ) Evidence disease progression within 6 month start study OR symptomatic disease ( medullary thyroid cancer subject ) Not candidate surgical resection , external beam radiotherapy , radioiodine therapy , local therapy At least 18 year age Undifferentiated/anaplastic thyroid cancer Untreated symptomatic brain metastasis Prior malignancy , unless cure treatment evidence disease great equal 3 year start study ( history thyroid cancer , situ cervical cancer , basal cell cancer skin exception ) Myocardial infarction unstable cardiac condition ( e.g. , congestive heart failure , unstable angina ) within 1 year start study Arterial thrombosis deep vein thrombosis within 1 year starting study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Thyroid cancer</keyword>
	<keyword>Advanced thyroid cancer</keyword>
	<keyword>Metastatic thyroid cancer</keyword>
	<keyword>Medullary thyroid cancer</keyword>
	<keyword>Follicular thyroid cancer</keyword>
	<keyword>Papillary thyroid cancer</keyword>
	<keyword>Hurthle cell thyroid cancer</keyword>
	<keyword>Thyroid cancer treatment</keyword>
	<keyword>Differentiated thyroid cancer medullary thyroid cancer</keyword>
</DOC>